During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients.

译文

在过去的十年中,不同的研究已经趋同,以证明银屑病患者的合并症患病率很高。尽管因果关系尚未完全阐明,但遗传关系,炎症途径和/或常见的环境因素似乎是牛皮癣和代谢合并症发展的基础。银屑病作为一种全身性疾病的概念引起了科学界的关注,以研究治疗干预对银屑病患者最普遍合并症的发生和演变的影响程度。这项研究提供了巴西可用的银屑病免疫生物学治疗 (英夫利昔单抗,阿达木单抗,依那西普和乌司他单抗) 对与银屑病相关的主要合并症的影响的科学证据。它强调了炎症负担对患者临床结果的重要性,不仅对疾病活动,而且对合并症。从这个意义上讲,无论是免疫生物学还是经典的全身治疗,都可以有效控制银屑病患者的炎症负担。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录